Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S100 calcium-binding protein A14 (S100A14) is a low-molecular-weight member of the S100 protein family, characterized by EF-hand calcium-binding motifs. Despite being classified in this family, human S100A14 does not bind calcium with significant affinity due to changes in its canonical EF-hand structure. Functionally, S100A14 regulates cell survival and apoptosis through modulation of p53/TP53 levels and impacts cell migration by controlling MMP2, a matrix protease. It interacts with the receptor for advanced glycation end products (RAGE), triggering associated signaling pathways. S100A14 is primarily a cytoplasmic protein expressed in specific tissues, with expression often reduced in cancerous cells and linked to increased metastasis, suggesting a tumor suppressor role. There are no clinically approved drugs specifically targeting S100A14, but its expression may have biomarker potential in cancer settings. The protein is studied for possible roles in cancer and inflammation, but significant challenges remain for therapeutic exploitation due to redundancy and overlap within the S100 protein family.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S100 calcium-binding protein A14 (S100A14).